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ABSTRACT 
 
Chromatin structure, determined in part by DNA methylation, is established during differentiation and prevents expression of genes 
unnecessary for the function of a given cell type. We reported that DNA methylation and chromatin structure contributes to lymphoid-
specific ITGAL (CD11a) and PRF1 (perforin) expression. We used bisulfite sequencing to compare methylation patterns in the ITGAL 
promoter and 5' flanking region of T cells and fibroblasts, and in the PRF1 promoter and upstream enhancer of CD4+ and CD8+ T 
cells with fibroblasts. The effects of methylation on promoter function were tested using regional methylation of reporter constructs, 
and confirmed by DNA methyltransferase inhibition. The relationship between DNA methylation and chromatin structure was 
analyzed by DNaseI hypersensitivity. Herein we described the methods and results in greater detail. 
 
 
INTRODUCTION 
 
DNA methylation in vertebrates refers to the methylation of 
deoxycytosine (dC) bases in CG pairs, and is associated with 
gene silencing. DNA methylation is essential for mammalian 
development (1), and contributes to gene silencing in 
differentiation, genomic imprinting, X chromosome inactivation, 
and suppression of parasitic DNA (2). Acquired changes in 
DNA methylation patterns have been implicated in the changes 
in gene expression that contribute to carcinogenesis, 
autoimmunity and aging (3). The importance of DNA 
methylation in normal and pathologic cellular processes has 
stimulated a growing interest in how DNA methylation 
suppresses gene expression, and in examining how changes in 
methylation patterns affect gene expression. 
 
DNA methylation can inhibit gene expression by several 
mechanisms. The methylation of promoter sequences inhibits the 
binding of some transcription factors. Members of the 
methylcytosine binding protein family, such as methyl-CpG-
binding protein 2 (MeCP2), specifically bind methylated DNA, 
blocking access of other factors required for gene transcription. 
More importantly, though, the binding of methylcytosine binding 
proteins to methylated DNA recruits chromatin inactivation 
complexes containing co-repressors and histone deacetylases, 
leading to a change in the chromatin structure from an open, 
transcriptionally permissive form to a more compact, inactive 
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form, inaccessible to the transcription machinery (1). In general, 
methylation of sequences in or near regulatory elements have 
suppressive effects on gene expression, while methylation of 
coding sequences has little to no effect (4). 
 
Several strategies have been devised for the quantitative 
assessment of total genomic deoxycytosine (dC) and 
deoxymethylcytosine content, as well as the methylation status 
of specific sequences. These are the subject of a recent review 
(5). At present, the most precise and generally applicable 
techniques for sequence-specific methylation analysis rely on 
bisulfite modification of DNA. Treating DNA with bisulfite 
deaminates cytosine bases to form uracil, but does not affect 
methylcytosine. Thus, PCR amplification and sequencing of 
bisulfite treated DNA allows precise quantitation of the 
methylation status of any desired CG pair (6). This approach, 
coupled with regional methylation of dC bases in promoter 
reporter constructs and DNaseI hypersensitivity analysis of 
chromatin structure in the region, provides information 
regarding both the presence and functional significance of the 
methylation patterns. Further confirmation may be obtained by 
demethylating DNA with the irreversible DNA 
methyltransferase inhibitor 5-azacytidine (5-azaC), then 
comparing effects on gene expression and methylation patterns. 
 
In this report we describe the methods utilized to compare the 
methylation patterns of the ITGAL (CD11a) promoter in T cells 
and fibroblasts, and of the PRF1 (perforin) promoters in T cells, 
an NK cell line and in fibroblasts, and how cassette or “patch” 
methylation may be used to test the effects of regional 
methylation on ITGAL and PRF1 promoter function. We also 
describe the use of DNaseI hypersensitivity assays to probe the 
chromatin structure around the same genes in representative 
cells with differential CD11a and perforin expression, and the 
use of DNA methyltransferase inhibition to confirm 
transcriptionally relevant changes in DNA methylation patterns.  
MATERIALS AND METHODS 
 
Cell and cell lines 
 
T cells were isolated from the peripheral venous blood of healthy 
donors by density gradient centrifugation followed by e-rosetting. 
CD4+ and CD8+ subsets were isolated using Miltenyi beads and 
protocols provided by the manufacturer (Miltenyi, Auburn, CA). 
Purity was checked by flow cytometry and was typically > 94% 
CD4+ or CD8+. Where indicated the T cells were stimulated for 
24 hours with 1 µg/ml phytohemagglutinin (PHA), then treated 
with 5-azaC or 2-deoxy-5-azaC (Sigma, St. Louis, MO) for an 
additional 72 hours as described (7, 8). Dermal fibroblasts from a 
healthy donor were donated by Dr. Samir Hanash, and synovial 
fibroblasts from a patient with osteoarthritis were provided by 
Dr. C. William Castor. YT cells, a perforin-expressing NK cell 
line, were provided by Dr. Y. Tagaya (National Cancer Institute, 
Bethesda, MD) and cultured as described (7). Jurkat cells (E6-1), 
a generous gift from Dr. Arthur Weiss, were cultured as 
previously described (9). SAM-19 cells were donated by Dr. 
Mathias Lichtenheld and cultured as described (7).  
 
Bisulfite genomic sequencing 
 
1-5 µg of purified DNA was treated with sodium bisulfite (10), 
then the desired sequences were amplified in sequential 
fragments using nested PCR. The primers were designed to 
account for the conversion of dC to dU by the bisulfite and avoid 
CG pairs, and EcoRI sites were added to the forward primers, and 
XbaI to the reverse, to facilitate cloning.  
 
 
The primers used for perforin were: 
 
Distal 1st: Forward: 5'-AGTGAATTCTGAAGTTGGGATTAGAATTTGTTTAGATTTTGT-3' 
Reverse: 5'-TAATCTAGAACCTAACCCTTCTTAAATATCAAAACCTATAA-3' 
Distal 2nd: Forward: 5'-TTTGAATTCAGATATTTTGTAGGATTTTTATGTTTTTTAAAT-3' 
Reverse: 5'-TCTTCTAGACCACTTCCTACTCAACCTACATCCCACCCTAA-3' 
 
Proximal 1st: Forward: 5'-ATTGAATTCTAATTTTTAGGGTTTATATGATTTATAATTTT-3' 
Reverse: 5'-TCCTCTAGAAATAACATCAACCCCCCAAACAACCCACTATAA-3' 
Proximal 2nd: Forward: 5'-AAGGAATTCAGGTATAGTGAGGTTGAAGAATTTTATTAGTTT-3' 
Reverse: 5'-TCCTCTAGACAACCACCACTCACATCACTTCTACTTCCTA-3' 
 
The primers used for CD11a were: 
 
Distal 1st: Forward: 5'-GAAGAATTCGTAGGTTGGTTTGAGTGTAGTGGTGTTTAAAAT-3' 
Reverse: 5'-CTCTCTAGAACTAAAACCACAAATACATACCACCATACCTAA-3' 
Distal 2nd: Forward: 5'-AAGGAATTCTTTTGTTTTAGTTTTTTAAGTAGTTGGGATTAT-3' 
Reverse: 5'-CCCTCTAGAATCTTAAACTCCTATACTCAAATAATCCTCCTA-3' 
 
Middle 1st: Forward: 5'-TAGGAATTCTATTTGAGTATAGGAGTTTAAGATTAGTTTGGGT-3' 
Reverse: 5'-AAATCTAGAATACAAACTCACTAACTATAATTCCAACCCTTTT-3' 
Middle 2nd: Forward: 5'-AGGGAATTCGGTATGTATTTGTGGTTTTAGTTATTTAGAGT-3' 
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Reverse: 5'-ATATCTAGATCTCTTAAAACCAAAAATCAAAACCAACCTAAA-3' 
 
Proximal 1st: Forward: 5'-ATATCTAGACCCTTTAACCTCTTACAATAATACTTTCTCACAA-3' 
Reverse: 5'-TTAGAATTCAAATGGGTTAAATATATTGTTTTGTTTTGTAATTTGT-3' 
 
Proximal 2nd: Forward: 5'-TTTGAATTCATTTTTTAAGGTTTAGAGAAAGTTTTTATTTTT-3' 
Reverse: 5'-CAATCTAGATTTCTCACAAAAACAACAAACTAATAACACTAA-3' 
 
PCR conditions were as follows: 94°C for 2 min, and 5 cycles of 
94°C for 1 min, 60°C for 2 min, 72°C for 3 min, then 25 cycles 
of 94°C for 30 sec, 60°C 2 min, 72°C 1 min 30 sec and finally 6 
min at 72°C. The PCR mixture contained thermophilic DNA 
polymerase 1x buffer, magnesium free with 1.25 units of Taq 
DNA polymerase (Taq DNA polymerase in storage buffer B, 
Promega, Madison WI), 3.4 mM MgCl2, 0.5 µm of each primer, 
and 0.24 mM dNTPs in a total volume of 25 µl. The second 
round of PCR was performed with 0.5 µm of nested primers, 
and the PCR conditions were the same as the first except that 
the total volume was 50 µl. The amplified fragments were 
cloned into PBS+ (Stratagene, La Jolla CA), and 5 independent 
clones for each of the amplified fragments were sequenced by 
the University of Michigan Sequencing Core.  
 
Patch methylation and transient transfections 
 
A 1.9kb XhoI fragment containing the human ITGAL promoter 
and 5' flanking region or a 1459-bp fragment encoding the 
perforin promoter and proximal enhancer were cloned into the 
luciferase-containing reporter vector pGL3-Basic (Promega). 
Appropriate restriction sites were engineered into the fragments 
to permit excision of the relevant regions using the QuikChange 
site-directed mutagenesis kit (Stratagene) and effects on 
promoter function excluded by transient transfection (7, 10). 
The regions of interest were then excised using the appropriate 
restriction endonucleases, gel purified, and methylated with SssI 
and S-adenosylmethionine (both from New England Biolabs, 
Beverly, MA) using instructions provided by the manufacturer. 
The methylated fragments were then ligated back into the 
expression constructs and methylation confirmed by digestion 
with appropriate methylation sensitive restriction endonucleases. 
Controls included mock methylated constructs similarly 
generated but omitting the SssI (7, 10). The methylated or mock 
methylated pGL3-ITGAL constructs were then transfected into 
Jurkat cells, and the pGL3-PRF1 constructs were transfected 
into SAM-19 cells, using electroporation and previously 
described protocols (7, 10). β-galactosidase or Renilla luciferase 
expression constructs (pRL-CMV; Promega) were used as 
transfection controls. Twenty-four hours later the cells were 
washed twice with PBS, suspended in 400 µl reporter lysis buffer 
(Promega), and lysed by freeze/thaw. Insoluble material was 
removed by centrifugation and luciferase or β-galactosidase 
measured. Briefly, β-galactosidase determinations were 
performed using the Galacto-Light system as per the 
manufacturer's protocol (Tropix, Bedford, MA) while luciferase 
assays were performed using the Dual-Luciferase Reporter Assay 
Kit (Promega) and instructions provided by the manufacturer, 
measuring fluorescence with a Turner Designs (Sunnyvale, CA) 
luminometer.  
 
DNase1 hypersensitivity 
 
DNase1 hypersensitivity assays were performed as described (7, 
11). Briefly, isolated nuclei were treated with 0, 40, 80, or 160 
U/ml DNaseI (Worthington, Lakewood, NJ) at room 
temperature for 3 minutes, then the reaction was stopped with 20 
mM EGTA/1% SDS and DNA isolated, digested with EcoRI for 
PRF1 or SacI for ITGAL, fragments fractionated by agarose gel 
electrophoresis, then transferred to nylon filters. The filters were 
hybridized with a 32P-labelled 277 bp fragment excised with 
EcoRI and XbaI (-1410 to -1133 relative to the transcription start 
site) from a 1459 bp fragment encoding the perforin gene 
promoter and 5' flanking region, or with a fragment spanning bp 
+1060 to +1264 (relative to the transcription start site) of the 
ITGAL gene, amplified by PCR (7, 11).  
 
RESULTS 
 
Methylation status of the ITGAL and PRF1 promoters 
and 5' flanking regions in expressing and 
nonexpressing cells 
 
ITGAL promoter methylation patterns were compared in 
fibroblasts and T lymphocytes as representative nonpermissive 
and permissive cell types. Figure 1A shows the ITGAL promoter 
numbered relative to the transcription start site (12). There are 22 
potentially methylatable CG pairs between the 5' end of the 
fragment and the transcription start site, and 5 following. For 
reference, a region containing Alu elements and the 
transcriptionally relevant PU.1 and Sp1 sites are also shown (12). 
DNA was isolated from synovial or dermal fibroblasts, treated 
with bisulfite, then the ITGAL promoter and 5' flanking region 
were amplified, cloned, and 5 fragments sequenced from each 
region. Figure 1B shows the methylation status of each CG pair 
averaged over the 10 fragments from the 2 fibroblast types. 
Nearly all CG pairs are relatively heavily methylated (> 50%) in 
the DNA from both lines. Figure 1C shows the methylation 
pattern from the same region in T lymphocytes isolated from 4 to 
6 healthy donors. The transcribed region is completely 
demethylated in all fragments from the 4 healthy subjects 
examined, while most of the sequence 5' to the transcription start 
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site was partially methylated in all controls. Of note is the region 
containing Alu elements, identified by the bar, which is more 
heavily methylated in all subjects, consistent with reports that 
repetitive DNA sequences are usually heavily methylated (13). 
 
 
 
Fig. 1: ITGAL promoter methylation. A. ITGAL promoter structure. The 
ITGAL promoter is shown, numbered relative to the transcription start site. 
Deoxycytosine residues in CG pairs are represented by the filled circles, the 
transcription start site by an arrow, and the PU.1 and Sp1 binding sites by lines. 
The horizontal line indicates a region containing Alu elements. B. ITGAL 
promoter methylation in fibroblasts. DNA was isolated from two fibroblast cell lines, 
treated with bisulfite, then the ITGAL promoter amplified in 3 regions. For each 
amplified region, 5 fragments were cloned and sequenced. The filled circles on 
the X axis represent each potentially methylatable dC residue, and the higher 
filled circles represent the average methylation for each site of the 5 sequenced 
fragments from both fibroblast lines. Again, the horizontal line indicates a region 
containing Alu elements. C. ITGAL promoter methylation in T cells. T cell DNA was 
similarly isolated, treated with bisulfite, amplified, and sequenced. The region 
from -1261 to -68 represents the average methylation of 5 fragments from each 
of 6 donors, while the remainder of the sequence represents the average 
methylation of 5 fragments from each of 4 normal donors. Again, the horizontal 
line indicates a region containing Alu elements. Modified from original published 
in Blood, 2002. 
 
Perforin promoter methylation in T cells, NK cells 
and fibroblasts 
 
A similar approach was used to compare PRF1 methylation 
patterns in YT cells, a human NK cell line that constitutively 
expresses perforin, and fibroblasts, which do not. Key elements 
of the human PRF1 promoter and 5' flanking region are shown in 
Figure 2A. The first 1300 bp 5' to the transcription initiation site 
contains 29 potentially methylatable CG pairs. The first 55 bp 5' 
to the start site contains a core promoter with a GC box. A series 
of repetitive elements is located between -396 and -83, and a 
region containing enhancer elements is located between -1136 
and -983 (14, 15). Relevant transcription factor binding sites are 
also shown. The methylation pattern of this region was then 
compared in YT cells and fibroblasts using the same techniques 
applied to the ITGAL promoter. Figure 2B shows the average of 
the 10 determinations for each CG pair in the PRF1 promoter of 
the two fibroblast lines, and Figure 2C shows the methylation 
status of each CG pair in four to five fragments from the YT 
cells. The region is largely methylated in fibroblasts. In contrast, 
only a single methylated dC base was detected in perforin-
expressing YT cells. 
 
These results were then confirmed in primary CD4+ and CD8+ 
T cells. In cytotoxic CD8+ T cells, perforin expression is 
regulated by signals from the IL-2 receptor activating STAT5, 
which then binds the enhancer region shown in Figure 2A (15). 
However, primary CD4+ T cells do not normally express the 
gene (7). Figure 2D shows the methylation pattern of the same 
region in CD4+ T cells from 6-7 normal individuals. The region 
from -1326 through-650 is relatively heavily methylated, while the 
more proximal CG pairs become progressively less methylated 
the closer they are to the transcription start site, with most of the 
methylated residues in the proximal sequences located in the 
region containing repetitive elements (Fig. 2A). Figure 2E shows 
the average methylation status of the same region in CD8+ T 
cells isolated from 4-5 healthy subjects. Overall, the entire region 
tends to be less methylated in CD8+ T cells compared to CD4+ 
cells (mean fraction methylated 0.23 vs 0.48, CD8 vs CD4, p < 
0.001 by paired t-test). The region from -1326 to -1000 is less 
methylated than the corresponding region in the CD4+ T cells 
(0.89 vs 0.52 for the analyzed region, CD4 vs CD8, p = 0.003). 
The region from -1000 to -599, flanking the enhancer elements 
(Fig. 3A), is also significantly (p = 0.001) less methylated in 
CD8+ T cells relative to CD4+ T cells (mean fraction methylated 
0.41 vs 0.71), although there is one exception at -720. The region 
from -457 to the transcription start site was also less methylated 
in the CD8+ T cells (0.21 vs 0.07, CD4 vs CD8, p < 0.001). 
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Fig. 2: PRF1 promoter methylation. A. PRF1 promoter structure. The positions 
of the transcription initiation site, transcription factor binding sites, repetitive 
elements, and enhancer elements are identified. Each shaded circle identifies a 
potentially methylatable CG pair. B. PRF1 promoter methylation in fibroblasts. 
DNA was isolated from two fibroblast lines and bisulfite treated. Then the 
region shown in A was amplified in two fragments (-1326 to -599 and -457 to -
4). For each amplified fragment, five fragments from each line were cloned and 
sequenced. Results are presented as in figure 1, and each point represents the 
mean fraction methylated of each CpG pair using 10 sequenced fragments from 
the two lines. C. PRF1 promoter methylation in YT cells. DNA was isolated from YT 
cells, and the mean methylation of each CG pair was determined as in B. D. 
PRF1 promoter methylation in CD4+ T cells. DNA was isolated from primary CD4+ 
T cells and the average methylation for each methylatable dC determined as in 
panel B. Results represent the mean methylation of 35 fragments from 7 donors 
(-1326 to -599) or 30 fragments from 6 donors (-457 to -4). E. PRF1 promoter 
methylation in CD8+ T cells. DNA from primary CD8+ T cells was analyzed as in 
panel D. Results represent the mean methylation of 30 fragments from 6 donors 
(-1326 to -599) or 25 fragments from 5 donors (-457 to -4). Copyright 2003 - 
Journal of Immunology, reproduced with permission. 
Effects of methylation on ITGAL and PRF1 promoter 
and enhancer function 
 
The relative importance of sequence specific methylation can be 
determined using regional or “patch” methylation. The approach 
used by our group is to excise the region of interest from a 
reporter construct, methylate the fragment in vitro with SssI and 
S-adenosylmethionine, ligate the methylated fragment back into 
the construct, and compare expression of the methylated 
construct and controls in transfected cells (7, 10).  
 
The effect of methylation of the ITGAL promoter 5' flanking 
region was determined by first inserting an NdeI site into the 
ITGAL promoter at bp -382. The regions from -1818 to -382 or 
from -382 to +79 were then excised, methylated in vitro, ligated 
back into the construct, and transfected into Jurkat cells. Figure 
3A shows that methylation of the region from the 5' end of the 
cloned promoter fragment to -382 partially suppresses promoter 
activity relative to controls, consistent with reports that 
methylation can suppress promoter function from a distance (1). 
Methylation of the region containing the active promoter (-362 to 
+79) suppressed to a greater degree. These studies suggest that 
ITGAL promoter activity is methylation sensitive. 
 
Fig. 3: Methylation suppresses ITGAL and PRF1 promoter function. A. 
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Effect of methylation on ITGAL promoter function. The regions from -1818 to -362 
and -362 to +79 were excised, methylated with SssI in vitro, ligated back into a 
luciferase reporter construct, and transfected into Jurkat cells, using 
cotransfection with ß-galactosidase as a control. Controls consisted of similar 
preparations but without the addition of SssI. The results are presented as the 
ratio of luciferase/ß-galactosidase expression in arbitrary units standardized to 
the mock-methylated controls and represent the mean±SEM of 5 experiments 
for the region from -1818 to- 362 and 4 experiments for the region from -362 to 
+79. B. Effect of methylation on perforin gene promoter function. A 1459-bp perforin gene 
promoter fragment was cloned into a reporter construct containing a firefly 
luciferase reporter gene. The indicated regions, numbered as in Figure 2A, were 
excised, methylated in vitro, religated into the reporter construct, and then 
transfected into SAM-19 cells. The solid bars represent the methylated construct; 
and the open bars the mock methylated constructs. Results are expressed relative 
to β-galactosidase or Renilla luciferase reporter constructs and are standardized 
to the mock methylated control. Results represent the mean ± SEM of four 
independent experiments for the first two data sets, and the mean ± SEM of two 
independent experiments for the second two data sets. Figure 3A: Copyright 
2002 - Blood, reproduced with permission. Figure 3B: Copyright 2003 – Journal of 
Immunology, reproduced with permission. 
 
Similar studies examined the functional effects of methylation on 
the PRF1 gene. These studies used a previously described 1459-
bp fragment containing the perforin promoter and upstream 
enhancer driving a firefly luciferase reporter gene (15). An NdeI 
site was inserted at -290, and a StuI site at -14. The region from -
1410 to -290 was then excised with EcoRI and NdeI, and the 
region from -1410 to -14 with EcoRI and StuI. The fragments 
were purified, similarly methylated with Sss1 and S-
adenosylmethionine, ligated back into their respective reporter 
constructs, purified, and transfected into SAM-19 cells. 
Methylation of both regions inhibited promoter function, with 
methylation of -1410 to -14 giving slightly greater suppression 
(Fig. 3B). This suggests that hypomethylation of the core 
promoter is insufficient to permit gene expression when the 
more 5' sequences are methylated. Figure 3B also shows that 
methylation of the promoter 5' flanking sequence (-979 to -527) 
decreased promoter function by ~70%. In contrast, methylating 
the distal 5' region (-1410 to -979) only decreased function by 
~10%. This suggests that the methylation status of the region 
linking the promoter and enhancer, hypomethylated in CD8+ 
relative to CD4+ T cells, is important in PRF1 gene expression. 
 
DNA demethylation and gene activation with DNA 
methylation inhibitors 
 
The effects of DNA methylation on gene expression can be 
confirmed using the irreversible DNA methyltransferase 
inhibitor 5-azaC. 5-azaC is a cytosine analog that is incorporated 
into newly synthesized DNA, where it covalently binds DNA 
methyltransferases as they methylate the purine ring. This 
depletes cellular DNA methyltransferase pools and results in 
hypomethylation of the newly synthesized DNA strand. The cell 
retains a fully methylated parent strand. Following a second 
round of cell division, half the daughter cells will have 
symmetrically hypomethylated DNA, while the other half will 
have fully methylated DNA (16). Thus, at most half the cells will 
be affected by one treatment, and effects are usually not seen 
until after 2 rounds of cell division (16). Increased expression 
will be seen in those genes for which the cells express the 
necessary transcription factors, but which were suppressed by 
DNA methylation.  
 
The effects of DNA methylation on PRF1 expression were 
confirmed by treating PHA stimulated CD4+ and CD8+ T cells 
with 5-azaC. Perforin expression increased in both cell types at 
the mRNA and protein levels (7). Figures 4A and 4B show the 
methylation patterns of the distal 12 CG pairs in untreated and 5-
azaC treated CD4+ T cells. The distal region is nearly completely 
methylated in the PHA stimulated CD4+ T cells, similar to that 
observed in unstimulated cells (Fig. 2). 5-azaC demethylates the 
region between -600 and -900. Figures 4C and 4D show similar 
studies in untreated and 5-azaC treated CD8+ T cells. Again, 
there is a preferential demethylation of the region between -600 
and -900. This is the same region differentially methylated 
between CD4+ and CD8+ T cells, and which when methylated 
suppresses promoter function. These results lend further support 
to the contention that methylation of this region suppresses 
perforin expression in T cells. 
 
 
Fig. 4: Effect of 5-azaC on PRF1 promoter methylation. A. DNA was 
isolated from 3 PHA stimulated CD4+ T cell lines and methylation patterns 
determined as in figure 2, sequencing 5 cloned fragments from each of the 3 
lines. Results represent the mean fraction methylated of the 15 determinations. B. 
The 3 CD4+ T cell lines shown in panel A were treated with 5-azaC, then DNA 
was isolated and methylation patterns were determined as in panel A. C. 
Methylation patterns were determined in 3 PHA stimulated CD8+ T cell lines, 
using the approach described in panel A. D. Methylation patterns were 
determined in the 3 PHA stimulated, 5-azaC treated CD8+ T cell lines using the 
approach described in panel B. Copyright 2003 – Journal of Immunology, 
reproduced with permission. 
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Comparison of the chromatin structure near the 
ITGAL and PRF1 promoter in expressing and 
nonexpressing cells with DNaseI digestion 
 
Chromatin structure around the ITGAL gene was also 
compared in T cells and fibroblasts using DNaseI 
hypersensitivity. Transcriptionally inactive chromatin is typically 
characterized by a condensed, nonpermissive configuration, 
inaccessible to transcription factors. Initiation of transcription 
requires first a remodeling of the chromatin, such that promoter 
sequences become accessible to transcription factors. The open, 
permissive configuration also becomes accessible to the 
endonuclease DNaseI. Limited digestion of intact chromatin 
with DNaseI results in cleavage at these sites, typically in 
transcriptionally relevant regions. The sites may be mapped by 
secondary digestion with appropriate restriction endonucleases 
and traditional Southern blotting, using probes to the ends of 
restriction fragments (17).  
 
DNaseI hypersensitivity assays were used to determine if DNA 
hypomethylation correlated with a transcriptionally permissive 
chromatin configuration in the ITGAL gene. Nuclei were 
isolated from normal human T cells and fibroblasts then 
digested with increasing amount of DNaseI. DNA was then 
isolated, digested with SacI, and the fragments analyzed by 
southern blotting using a probe corresponding to bp +1060 to 
+1264 relative to the transcription start site. Figure 5A shows an 
approximately 3.2 kb fragment resulting from SacI digestion in 
both T cells and fibroblasts. Digestion with low concentrations 
of DNaseI causes the appearance of a prominent 1.4 kb band in 
T cells but not fibroblasts, while the highest concentration tested 
appears to cause some nonspecific digestion in both cell types. 
The cleavage site maps to the region just 5' to the transcription 
start site in T cells, and hypomethylated in T cells relative to 
fibroblasts (Fig. 5B). This indicates that this hypomethylated 
region has a structure making the DNA more accessible to the 
enzyme in T cells, consistent with active chromatin. 
 
Similarly, chromatin structure near the PRF1 promoter was 
compared in YT cells and fibroblasts, using limited DNaseI 
digestion. Nuclei were isolated and briefly digested with 
increasing amounts of DNaseI. DNA was then isolated, digested 
with EcoRI, and the fragments analyzed by Southern blotting, 
shown schematically in Figure 6A. A 2.65-kb EcoRI-EcoRI 
fragment is seen in both cells (Fig. 6B). DNaseI digestion of YT 
cells releases 1.2-, 0.6-, 0.5-, and 0.4-kb fragments. In contrast, 
fibroblast DNA is resistant to DNaseI in this region. The 
DNaseI studies indicate that the perforin gene 
promoter/enhancer fragment was inaccessible to the enzyme in 
fibroblasts, but not in YT cells. Similar studies comparing 
DNaseI hypersensitive sites in primary CD4+ and CD8+ T cells 
demonstrated the same 1.2 kb fragment, mapping to the minimal 
promoter, in both cell types (Fig. 6C). However, CD8+ cells also 
demonstrate a DNaseI hypersensitive site at 0.6 kb, indicating an 
open configuration near the enhancer region. This is just 5' to the 
region differentially methylated between CD4+ and CD8+ T 
cells (Fig. 3D), where promoter function was suppressed by 
methylation of this region (Fig. 4B). This is also adjacent to the 
STAT5 binding site regulating perforin expression (14). Together 
this suggests that methylation of this region may contribute to a 
transcriptionally inactive configuration in CD4+ T cells. 
 
Fig. 5: ITGAL promoter chromatin structure in fibroblasts and T cells. A. 
Fibroblasts and freshly isolated T cells were homogenized in PBS then treated 
with 0, 40, 80 or 160 U/ml DNaseI. DNA was then isolated, digested with SacI, 
fractionated by agarose gel electrophoresis, transferred to nylon filters, 
hybridized with a 32P-labeled cDNA probe amplified from bp 1060-1264 of the 
ITGAL gene, and developed using a PhosphoImager. Fragment size is shown in 
the right column. B. Schematic diagram showing the 3.2 kb SacI - SacI fragment, 
the relative size and location of the probe, and the approximate location of the 
1.4 kb fragment. The broken arrow represents the transcription start site. 
Copyright 2002 – Blood, reproduced with permission. 
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Fig. 6: PRF1 promoter chromatin structure in fibroblasts, NK cells, and 
CD4+ and CD8+ T cells. A. Map of the region analyzed, indicating the 2.65 kb 
EcoR1 - EcoR1 fragment, the transcription start site (arrow), and the location of 
the fragment used to probe the blot. The distance from the 5' EcoRI site to the 
transcription start site is 1.4 kb. B. Nuclei were isolated from YT cells or 
fibroblasts (left panel), or CD4+ and CD8+ T cells (right panel). The chromatin 
was digested with 0, 40, 80, or 160 U/ml DNaseI, then Southern analysis 
performed as described in Materials and Methods. Fragment size in kb is shown 
in the middle of the figure. C. The arrows identify cleavage sites producing the 
1.2, 0.6, 0.5 and 0.4 kb fragments shown in panel B. The balloons again identify 
CG pairs. Copyright 2003 – Journal of Immunology, reproduced with permission. 
 
DISCUSSION 
 
In this report we describe the use of bisulfite sequencing, 
regional methylation of promoters in reporter constructs, 
treatment of S-phase cells with 5-azaC to determine effects of 
DNA methylation on ITGAL and PRF1 gene expression, and 
the use of DNaseI hypersensitivity assays to correlate the 
methylation status of the regulatory regions with chromatin 
structure. Bisulfite sequencing revealed that the ITGAL 
promoter is heavily methylated in fibroblasts but not T cells, and 
that methylation of the core promoter suppressed promoter 
function. Further, hypomethylation of the ITGAL promoter and 
5' flanking region correlated with the presence of a DNaseI 
hypersensitive site adjacent to the core promoter. These results 
indicate that ITGAL promoter methylation contributes to 
CD11a suppression in fibroblasts. The observation that 
hypomethylation correlates with a DNaseI hypersensitive site 
near the core promoter is consistent with evidence that DNA 
methylation contributes to gene silencing by attracting 
chromatin inactivation complexes promoting chromatin 
condensation into an inactive configuration (2, 4).  
 
Bisulfite sequencing of the PRF1 core promoter similarly 
demonstrated relatively complete methylation in fibroblasts but 
hypomethylation in CD4+ and CD8+ T cells. Again, 
hypomethylation of the minimal promoter correlated with the 
presence of a DNaseI hypersensitive site. However, in contrast to 
ITGAL, core promoter hypomethylation alone was insufficient 
to cause gene expression in CD4+ T cells. Hypomethylation of a 
region linking the core promoter with an upstream enhancer 
correlated with gene expression in CD8+ T cells, and 
demethylation of this region with 5-azaC induced perforin 
expression in CD4+ T cells as well as increasing expression in 
CD8+ T cells. Selective methylation of this region in reporter 
constructs suppressed promoter function, indicating 
transcriptional relevance. Finally, hypomethylation of the region 
linking the enhancer with the promoter coincided with the 
presence of a DNaseI hypersensitive site, again linking DNA 
hypomethylation with a permissive chromatin configuration. We 
have since used hypersensitivity analyses to identify a 
downstream enhancer demethylated and activated by 5-azaC to 
induce expression of the IgE FcRγ1 molecule, characteristic of 
effector T cells (unpublished results).  
 
However, DNA hypomethylation does not always correlate with 
DNaseI hypersensitivity. Bisulfite sequencing of the PRF1 
promoter and upstream enhancer region in YT cells, a 
transformed NK line, demonstrated nearly complete 
demethylation of the entire region. This is consistent with other 
reports that the DNA of transformed lines is generally 
hypomethylated, with the exception of certain CpG islands (18). 
However, despite the overall hypomethylation, the DNaseI 
hypersensitive sites were nearly identical in YT cells and the 
relatively more methylated CD8+ T cells. Similarly, the ITGAL 5' 
flanking region was largely demethylated in T cells, but the only 
DNaseI hypersensitive site detected was adjacent to the core 
promoter. It is likely that other determinants of chromatin 
structure, such as histone acetylation and/or methylation, also 
contribute to the formation of the hypersensitive sites. These may 
be identified using chromatin immunoprecipitation approaches 
(19). 
 
One of the strengths of bisulfite sequencing is its general 
applicability to nearly any desired sequence. Further, methylation 
patterns can vary on a clonal basis (7). By cloning and sequencing 
5 or more fragment from each amplified region studied, an index 
of clonal variability can be obtained. Alternatively, the PCR 
products may be directly sequenced, giving a average of the 
methylation status of each CG pair. One limitation of bisulfite 
sequencing is that the technique requires PCR amplification, and 
GC rich sequences may be difficult to amplify. The use of 
improved Taq polymerases, such as Platinum Taq PCRx DNA 
polymerase from Invitrogen (Carlsbad, CA) may help in this 
situation. Further, it is important to assure that the bisulfite 
conversion process is complete. The strategies described in the 
Protocols section help address this concern. Finally, once the 
importance of specific methylation changes is established, the 
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more rapid and technically less demanding methylation specific 
PCR assays may be used to quickly assess methylation status of 
the region for high throughput studies (5). This approach relies 
on amplifying bisulfite treated DNA with primers specific for 
sequences that would correspond to bisulfite modified or 
unmodified dC bases, depending on their methylation status, and 
determining the relative abundance of both amplified fragments. 
 
Regional or cassette methylation provides valuable supportive 
evidence for the relevance of methylation changes to gene 
expression. DNA methylation can suppress gene expression 
from a distance of up to 500-1000 bp (1), and it is important to 
determine if methylation changes some distance from a 
promoter are affecting promoter function. An example is shown 
in Figure 3B, where methylation of the most 5' sequences of the 
PRF1 promoter had minimal effect on promoter function, 
although changes in methylation of this region were detected in 
5-azaC treated T cells. Others have reported that strong 
promoters with only a few CG pairs may also be resistant to 
suppression by methylation (20), and cassette methylation may 
be used to verify the significance of methylation changes in 
similar situations. The limitations of this approach include the 
concern that while methylation can promote condensation of 
intact chromatin, the plasmids used in transient transfections 
may not necessarily assume the same configuration when 
methylated. 
 
The relative strengths and weaknesses of 5-azaC as a probe for 
methylation sensitive genes are well summarized in the literature 
(16, 21). 5-azaC has effects on a number of cellular processes 
including RNA and protein synthesis, while 2-deoxy-5-azaC is 
more potent and relatively more specific for DNA methylation, 
but is also more toxic to cells. Both also have a relatively narrow 
window between concentrations inhibiting DNA methylation 
and concentrations inhibiting DNA synthesis. Since the treated 
cells need to go through 2 rounds of cell division before changes 
in methylation sensitive genes occur (16), it is often necessary to 
test a range of concentrations to optimize changes in gene 
expression. It can also be useful to include treatment with 
hydroxyurea as control, as this agent will also inhibit DNA 
synthesis, but does not inhibit DNA methylation (22). Changes 
in gene expression similarly affected by 5-azaC and hydroxyurea 
are likely to be due to DNA synthesis inhibition. 
 
Overall, the relatively newer techniques of bisulfite sequencing 
and cassette methylation greatly augment the utility of the older 
techniques of 5-azaC treatment and DNaseI hypersensitivity 
analyses. The combination of these techniques now permits 
detailed analyses of how DNA methylation changes relate to 
changes in gene expression. This has utility in normal cellular 
processes such as differentiation, but also to pathologic states 
such as aging, autoimmunity and cancer (3). 
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PROTOCOLS 
 
Protocol I: Bisulfite Genomic Sequencing  
 
A. Equipment and kits 
 
1. Wizard DNA Clean-Up System (Promega) 
2. Thermocycler 
3. Agarose gel electrophoresis apparatus 
4. Water baths 
5. Microcentrifuge  
6. 1.5 ml microcentrifuge tubes 
7. Vacuum centrifuge  
8. QIAquick gel extraction kit (Qiagen, Valencia CA) 
 
B. Reagents 
 
1. 2 M NaHSO3: 3.8 gm in 10 ml ddH2O, mix by gentle shaking 
2. 0.2 M Hydroquinone: 0.220 gm in 10 ml dH2O, mix by gentle shaking 
3. 3.5 M NaOH 
4. 3.0 M NaOH 
5. 6M NH4oAc pH 7.0 
6. Glycogen 5 mg/ml in dH2O 
7. DNA: 0.05-0.50 g/µl in dH2O 
8. Mineral oil 
9. pBS vector + (Stratagene) 
10. Phenol/chloroform 
11. Tris-EDTA (TE: 10 mM Tris-HCl, pH 7.5, 0.1 mM EDTA. 
12. Appropriate restriction endonucleases 
 
C. Methods 
 
Bisulfite treatment 
 
1. Mix 45 µl DNA (~2-20 µg) with 5 µl NaOH in 1.5 ml microcentrifuge tubes, incubate at 37°C x 20 minutes in water bath. 
2. Add 517 µl NaHSO3 and 30 µl hydroquinone, vortex, concentrate liquid in tip by centrifugation, overlay with 150 µl mineral oil, 
incubate at 55°C x 18 h in water bath. 
 
Desalting 
 
1. Use the Wizard DNA Clean-Up System. Add 1 ml of the resin to 300 µl of the NaHSO3-treated DNA. 
2. Apply slurry to column, using vacuum to draw sample into the column. 
3. Wash column x3 with 1 ml 80% ethanol. 
4. Remove ethanol by centrifugation over an eppendorf tube at 10,000 X 2 min in microfuge. 
5. Elute DNA with 45 µl ddH2O, centrifuge at 14,000 X 5 min, then transfer to new 1.5 ml tubes. 
6. Add 5 µl 3M NaOH to each sample ([NaOH]final = 0.3 M), incubate 37°C x 15 minutes. 
7. Add 50 µl 6M NH4oAc ([NH4oAc]final = 3M) and mix. 
8. Precipitate DNA by adding 1 µl glycogen + 250 µl 95% ETOH, incubate at -80°C x 2-18 hrs. 
9. Centrifuge to collect precipitate, wash with 70% EtOH, dry in speedvac, redissolve in 50 µl ddH2O. 
 
PCR amplification, purification and digestion 
 
1. In designing primers avoid CG pairs and replace all dC bases with dT. For the final amplification include 5' EcoRI and 3' XbaI 
linkers at the ends of the primers for ease in cloning.  
2. Use nested PCR for optimal results. Protocols need to be established for each DNA fragment studied. 
3. Following PCR transfer 45 µl of PCR product to 1.5 ml Eppendorf tube, bring up volume to 200 µl with 155 µl Tris-EDTA (TE). 
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4. Extract once with 200 µl phenol/chloroform and once with 200 µl chloroform.  
5. Precipitate with 500 µl 100% ethanol, 20 µl 5M NaCl, 1 µl glycogen. Vortex mixture then incubate at -80°C, 2-18 hrs.  
6. Centrifuge 14,000 rpm/5min, wash precipitate with 70% ethanol, resuspend pellets in 15 µl TE. 
7. Digest PCR product with a suitable restriction enzyme to remove bisulfite unconverted DNA, i.e. the enzyme should recognize a 
sequence with at least one dC which would be converted to dT by bisulfite treatment, conferring resistance to digestion. 
8. Fractionate the digest using a 1% agarose gel, elute DNA in 20 µl ddH2O using Qiagen gel extraction kit. 
9. Ligate the PCR product into to the pBS+ (Stratagene) vector, clone and sequence using standard protocols. 
 
Protocol II: Cassette methylation 
 
Reagents and equipment 
 
A. Equipment and kits 
 
1. Qiagen Plasmid Maxi kit (Qiagen) 
2. QIAquick gel extraction kit (Qiagen) 
3. Amaxa Nucleofector apparatus and solutions or other electroporation apparatus 
4. Turner Designs or other luminometer 
5. Dual-Luciferase Reporter Assay Kit (Promega) 
6. Agarose gel electrophoresis apparatus 
7. Water baths 
 
B. Reagents 
 
1. Appropriate restriction endonucleases to excise fragment 
2. SssI methylase 4U/µl (New England Biolabs) 
3. 200x S-adenosylmethionine (SAM) (New England Biolabs) 
4. NE buffer 2 (New England Biolabs) 
5. PGL3-Basic (Promega) or EGFP-C1 (Promega) 
6. T4 DNA ligase, 10-20 U/µl (Promega) 
7. 10X T4 DNA ligase buffer (Promega) 
8. EtOH/NaoAc 
9. Glycogen 
10. Phenol/chloroform 
11. pRL-CMV (Promega) 
 
C. Methods 
 
1. Obtain cloned or PCR amplified promoter fragment. If amplified by PCR, be sure to confirm sequence to exclude Taq error. 
2. Clone the promoter into the Luciferase-containing reporter vector PGL3-Basic (Promega) or the eGFP containing report vector 
EGFP-C1 (Promega). 
3. Prepare plasmid DNA using the Qiagen Plasmid Maxi kit.  
4. Excise the regions of interest from 50 µg of DNA using the appropriate restriction endonucleases. If necessary restriction sites can 
be generated using the Quickchange site-directed mutagenesis kit (Stratagene), taking care to exclude the possibility that the 
mutations affect promoter function with appropriate transfection assays. 
5. Fractionate the digest by agarose gel electrophoresis and elute DNA using the Qiagen QIAquick gel extraction kit, saving both the 
vector and the excised fragment. Dissolve the DNA in 80 µl ddH2O.  
6. Methylation of excised fragment with Sss1 and SAM. Controls include a mock methylated fragment, prepared by omitting the Sss1. 
Mix the reagents as described in the table below. 
 
CpG methylation Mock methylation 
40 µl DNA 40 µl DNA 
16 µl 10 x NE Buffer 2 16 µl 10 x NE Buffer 2 
8 µl 20 x SAM (200x stock diluted 1:10 in ddH20) 8 µl 20 x SAM (200x stock diluted 1:10 in ddH20) 
8 µl Sss1  
88 µl ddH2O 96 µl ddH2O 
Total volume: 160 µl Total volume: 160 µl 
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Incubate the mixtures 37°C 18 hrs, then add another 4 µl Sss1 and 4 µl 20 X SAM into the CpG methylation sample, or SAM alone into 
control. Incubate mixture 37°C another 4 hours, then inactive Sss1 methylase by heating at 65°C for 20 min. Extract both the 
methylated and mock methylated fragment with phenol/chloroform, precipitate DNA with EtOH/oAc and glycogen, then resuspend 
in 20 µl ddH2O. Use 4 µl of the DNA solution to confirm methylation by digestion with the appropriate methylation sensitive enzyme 
and agarose gel electrophoresis. 
7. Religate fragment back into the promoter-reporter construct. Mix 16 µl methylated or unmethylated fragment, 4 µl of linear vector 
lacking the fragment, 4 µl 10X T4 DNA ligase buffer, 2 µl T4 DNA ligase, 14 µl ddH2O and incubate at 14°C 18-24 hrs. Extract 
with phenol/chloroform, precipitate with EtOH/oAc/glycogen, resuspend in 20 µl ddH2O, then check ligation by digestion of 5 µl 
with appropriate restriction endonucleases followed by agarose gel electrophoresis. 
8. Transfect the methylated or mock methylated constructs into appropriate cells by electroporation using Amaxa Nucleofection 
apparatus and the manufacturer's protocols. Use Renilla luciferase expression construct (pRL-CMV, Promega) as transfection 
control in same tube. 
9. Culture cells for 48 hours, wash twice with 1 x PBS, suspend in 400 µl reporter lysis buffer (Promega), and lyse by freeze-thaw in 
dry ice/acetone. Insoluble material is removed by centrifugation and luciferase assay performed using Dual-Luciferase Reporter 
Assay Kit (Promega) and instructions provided by the manufacturer, and measuring fluorescence with the luminometer.  
 
Protocol III: DNaseI Hypersensitivity Assays  
 
A. Equipment and kits 
 
1. 1 ml Dounce homogenizer 
2. Centrifuge 
3. Centrifuge tubes 
4. Microcentrifuge 
5. Microcentrifuge tubes 
6. Water baths 
7. Agarose gel electrophoresis apparatus 
 
B. Reagents 
 
1. PBS: 8 g/L NaCl, 0.2 g/L KCl, 1.44 g/L Na2HPO4, 0.24 g/L KH2PO , pH 7.4 
2. Trypsin-EDTA: 0.5 g/L trypsin, 0.2 g/L EDTA (Invitrogen) 
3. DNaseI (molecular biology grade, Worthington) 
4. DNaseI I buffer: 
 
Component Stock Final Amount for 50 ml 
HEPES pH 8.0 1 M 10 mM 500 µl 
KCl 3 M 50 mM 833 µl 
MgCl2 500 mM 5 mM 500 µl 
CaCl2 1 M 3 mM 150 µl 
NP40 100% 0.1% 50 µl 
Glycerol 100% 8% 4 ml 
*DTT 1 M 1 mM 50 µl 
 
*Add DTT just prior to use. 
 
5. DNaseI digestion stop buffer: 
 
Component Stock Final Amount for 15 ml 
EGTA 50 mM 20 mM 6 ml 
SDS 10% 1% 1.5 ml 
DNase-free H2O   7.5 ml 
 
6. DNase-free ribonuclease A (10 mg/ml, Invitrogen). 
7. Proteinase K (10 mg/ml, Invitrogen).  
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8. 3M sodium acetate. 
9. Phenol/chloroform/isoamyl alcohol (25:24:1). 
10. Isopropanol. 
11. Ethanol, 70%. 
12. TE: 10 mM Tris-HCl, pH 7.5, 0.1 mM EDTA. 
13. Gene-appropriate restriction enzyme with suitable 10x reaction buffer. 
14. 1x TAE: 20 mM Tris-acetate, pH 8.0, 1 mM EDTA 
15. Agarose, electrophoresis grade. 
16. 10x Loading buffer: 65% (w/v) sucrose, 10 mM Tris-HCl pH 7.5, 10 mM EDTA, 0.3% (w/v) bromphenol blue. 
17. 1kb ladder (Invitrogen). 
18. [α32P] dCTP (PerkinElmer, Boston MA). 
19. Random primer DNA labeling system (Invitrogen). 
20. PhosphorImager storage plates (Molecular Dynamics of Amersham, Piscataway, NJ), or X-ray film 
 
C. Methods 
 
Isolation of nuclei 
 
1. Adherent cells: For each 100x20 mm dish (1.5-2.0 x 107 cells), remove culture medium, rinse plate twice with PBS, add 1 ml 
Trypsin-EDTA and incubate at 37°C for 3-5 min. Dislodge the cells with gentle shaking, then immediately add back serum 
containing culture medium to quench the trypsinization. Transfer the cells to a centrifugation tube and collect by sedimenting at 
200 x g for 5 min at 4°C, then wash twice with cold PBS.  
 
Suspension cells: Harvest the cells (approximately 2x107) from the flask by sedimenting at 200 x g for 5 min at 4°C, then wash twice 
with cold PBS. 
 
2. Resuspend the cell pellet in 1.2 ml ice-cold DNase I buffer, and then disrupt cells on ice using a Dounce homogenizer 
(approximately 10 strokes).  Make 4 aliquots (280 µl each), keeping the aliquots at 4°C on ice.  
  
DNaseI treatment of nuclei 
 
1. Reconstitute vial with DNaseI buffer and glycerol according to the manufacturer's instructions, mix by gentle inversion, gently 
centrifuge to remove the liquid from the lid, and store aliquots (5 U/µl) at -80°C.  
2. For DNaseI digestions, it is often necessary to first establish the optimal amount of DNaseI, since the appropriate concentration 
can vary for different cell types. For T lymphocytes we incubate the four 280 µl aliquots with 0 40, 80, and 160 U/ml of DNaseI (0, 
2.2, 4.4 and 9.0 µl, respectively) at 25°C in a controlled temperature water bath for 3 min, then add 300 µl DNaseI stop buffer to 
stop the reaction.  
 
DNA purification, digestion and Southern blotting 
 
1. Add 5.8 µl DNase-free ribonuclease A (10 mg/ml) to each sample, incubate the mixture at 37°C for 2 hours, and then add 11.6 µl 
proteinase K (10 mg/ml) and incubate the mixture overnight at 55°C.  
2. Purify the DNA by adding 60 µl 3M sodium acetate pH 5.4 to each sample, extracting twice with 1 volume of 
phenol/chloroform/isoamyl alcohol, then centrifuge at 20,800 x g at room temperature in a microfuge for 5 min.  
3. Transfer the aqueous phase to fresh tubes, precipitate the DNA with 0.7 volumes of isopropanol, mix by inverting the tubes at 
least twice, incubate at -20°C for 1-2 h or overnight, then sediment the DNA by centrifugation at 20,800 x g 4°C for 10 min and 
rinse with ice cold 70% ethanol.  
4. Resuspend the DNA pellets in 31 µl TE. To check the size distribution of the cleavage products electrophorese 1 µl of sample 
through a 1% agarose gel in 1x TAE with 0.5 µg/ml ethidium bromide.  
5. Digest the DNA with an appropriate amount of the desired restriction endonuclease as follows. Using 1.5 ml microcentrifuge 
tubes, add 5 µl of the appropriate 10x restriction enzyme buffer, 30 µl of the purified DNA and DNase free H2O to a final volume 
of 50 µl. Add an appropriate amount of the restriction enzyme and incubate at 37°C overnight. 
6. Fractionate the digested DNA by electrophoresis through a 25 cm 1.2-1.5% agarose/TAE gel, using 2.0 v/cm (40 v) until the 
bromphenol blue tracking dye has migrated across ~ 80% of the gel using standard protocols.  
7. Transfer the DNA to a nylon filter, then hybridize to an α32P-labelled fragment from one end of the region of interest, labeled by 
random priming, and visualize bands using a PhosphorImager or X-ray film and standard Southern blotting methods. 
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Protocol IV: Treating cells with 5-azacytidine  
 
A. Equipment  
 
1. Analytical balance 
2. 0.2 micron sterilization filters and syringes 
3. Culture vessels 
4. Incubator 
 
B. Reagents 
 
1. 5-azaC or 2'-deoxy-5-azaC (Aldrich) 
2. Cultured cell lines in log phase growth 
 
C. Methods 
 
1. Dissolve 5-azaC or 2'-deoxy-5-azaC in PBS or tissue culture media. Typical concentrations for 5-azaC are 0.25-8.0 µM, with 1 µM 
most often being effective. 2'-deoxy-5-azaC is more specific for DNA methylation inhibition and is also more potent, so lower 
concentrations may be used. The solutions are typically made up 10-100X the desired concentrations. Both are unstable in aqueous 
media  and must be prepared just before use.  
2. Filter sterilize the stock solution. 
3. Add sterilized solution to cultures of cells in S-phase. Since concentrations of both compounds that inhibit DNA methylation are 
only slightly lower than concentrations inhibiting DNA synthesis, a range of concentrations are typically tested. Further, the 
purchased chemicals have some variability in potency, so the optimal concentration for each lot should be determined.  
4. Changes in gene expression are typically detected after 1-2 cycles of cell division, so initial studies should also include kinetic 
analyses. Significant cell death is also often seen.  
 
